HCG
Healthcare Global Enterprises Limited Q1 FY27: Revenue Up 13%, Adjusted Ebitda Grows 20%
Healthcare Global Enterprises Limited (HCG) reports Q1 FY27 results with 13% revenue growth, 20% Adjusted EBITDA, and improved margins.
Healthcare Global Enterprises Limited (HCG) has announced its Q1 FY27 results, showcasing a robust performance with a 13% year-over-year revenue growth to INR 6,951 Mn and a 20% increase in Adjusted EBITDA. The company’s margins improved to 19.4% from 18.2% in Q1 FY26, driven by strategic initiatives and operational efficiencies.
Revenue and Margins
The revenue growth was broad-based across all clusters, with the South region contributing 40% of the total revenue and showing a 16% year-over-year increase. The West region, contributing 43% of the revenue, saw a 9% growth, primarily driven by Maharashtra. The East region, accounting for 11% of revenue, experienced a 22% growth, boosted by a 25% increase in patient volumes. International business revenue grew by 9% to INR 208 Mn, supported by higher patient inflows for radiation oncology and PET cases.
Operational Highlights
HCG’s operational highlights include the addition of 121 beds in Q1 FY27, strengthening its leadership in the Bengaluru market. The company successfully completed a rights issue, enhancing its financial flexibility and strengthening its balance sheet. The leadership team remains fully onboarded, with a focus on driving productivity improvements and enhancing patient experience.
As HCG continues to execute its strategy, it remains well-positioned to fund future growth and create sustainable long-term value for its stakeholders.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Healthcare Global Enterprises Limited
Healthcare Global Enterprises Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.
Healthcare rises 12.4% over three months, with buying pressure holding steady. D/E of 1.86 is elevated. As a result, debt servicing will compress free cash flow in a high-rate environment. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. The stock holds at 57% of its 52-week range with RSI at 60. In other words, neither side has a clear edge right now. Revenue grows at 14.8% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Healthcare Global Enterprises Limited.
HCG
Healthcare Global Enterprises Limited (NSE: HCG) clears resistance, gains 5% intraday
Healthcare Global Enterprises Limited (NSE: HCG) stock breaks out, moving up 5% intraday to ₹710.0, clearing its 6M resistance trendline.
Healthcare Global Enterprises Limited (HCG) breaks out, gaining +5% to ₹710.0 on the NSE on 10 Aug 2026. This move follows the stock clearing its 6-month resistance trendline, a key technical signal indicating potential for further upside. HCG operates in the healthcare sector, specifically medical care facilities, and today’s breakout suggests strong momentum, possibly driven by the company’s recent announcements regarding its financial results and upcoming investor meetings.
Technical setup — trendlines & DMA
From a technical perspective, HCG’s current price is well above its 6-month support trendline, which ends at ₹605.39, indicating a robust uptrend. The stock has also surpassed its 6-month resistance trendline, which concluded at ₹699.68, by 1.45%, confirming the breakout. The 50-day moving average (DMA) at ₹644.7 is above the 200-DMA at ₹635.0, signaling a bullish trend. HCG is currently trading in the upper third of its 52-week range, suggesting that while there is room for further gains, the stock is already reflecting a significant portion of its potential upside.
Snapshot: ₹710.00 on 2026-08-10 (chart frozen at publication)
Fundamentals & business context
On the fundamental side, HCG’s price-to-earnings (PE) ratio of 719.0, coupled with a profit margin of 0.5%, raises questions about the valuation relative to current earnings. However, the company’s revenue CAGR of 14.8% over the past five years suggests that the market may be pricing in future growth. Institutional ownership stands at 17.4%, indicating a level of confidence from sophisticated investors. There is no specific NSE catalyst today, but the recent announcements and upcoming investor meetings could be contributing to the positive sentiment.
Algorithmic scorecard
The algorithmic scorecard reflects a technically strong but fundamentally weaker profile for HCG. Two of the strongest signals are the bullish trend, indicated by the 50-DMA being above the 200-DMA, and the strong momentum across various timeframes. These signals suggest that the stock is in an upward trajectory and has been gaining consistently. On the weaker side, the low profit margin of 0.5% and the high debt-to-equity ratio of 1.86 are significant risks. The low margin leaves little room for error, while the high debt level could constrain the company’s financial flexibility.
Company outlook
Management’s medium-term revenue growth estimate remains close to 15%, with expectations of some reduction in interest costs due to rights issue funds and debt repayment. The company plans to derive at least 75-80% of growth from existing hospitals with expansions, with the remainder coming from newer centers. There is a continued focus on margin expansion, cost management, and improving the quality of earnings. HCG aims to add 200+ beds across various locations over the next 24 months and plans to add about 1,000 beds by FY30, with 400 through Greenfield and 600 through Brownfield expansion.
Get all details on HCG — P&L, peers, shareholding and more on TradeAlone.
HCG
Healthcare Global Enterprises Limited (HCG) shows pressure after breakout, falls 5% intraday
Healthcare Global Enterprises Limited (NSE: HCG) shows pressure after breakout, falling 5% intraday to ₹648.8.
Healthcare Global Enterprises Limited (HCG) fell -5% today, marking a notable pullback after a strong run. The move comes as the stock approaches resistance at ₹669, just 3.2% away, and is currently extended 9% above its 50-DMA. HCG operates in the healthcare sector, specifically medical care facilities, and today’s decline appears to be a technical correction rather than a sector-wide phenomenon.
Technical setup — trendlines & DMA
From a chart perspective, HCG has broken out above its 6-month support trendline, which ends at ₹605.39, sitting 6.69% below today’s price. Resistance is at ₹669.36, a level the stock is currently 3.17% below. The 50-DMA at ₹630.7 is above the 200-DMA at ₹637.5, signaling a bearish trend, but the stock itself is trading well above both moving averages, indicating some strength. HCG is currently in the middle third of its 52-week range, suggesting that while there’s room for further upside, a significant portion of the move may already be priced in.
Snapshot: ₹648.80 on 2026-07-15 (chart frozen at publication)
Fundamentals & business context
On the fundamental side, HCG’s PE of 722.5 looks stretched given its thin profit margin of 0.5% and a declining profit CAGR of -22.3% over the past 5 years. However, the revenue CAGR of 14.8% indicates some growth momentum. The 16.5% institutional ownership suggests that smart money sees value in the company, though the negligible dividend yield and high debt levels are concerns. There was no NSE catalyst today, making the move primarily technical in nature.
Algorithmic scorecard
The overall algorithmic scorecard reflects a technically strong but fundamentally weak stock. Two of the strongest signals are the breakout above resistance levels with momentum and the consistent revenue growth every year, indicating exceptional business stability. On the flip side, the two weakest signals are the low profit margin of 0.5% and the high debt levels with a D/E ratio of 1.86, which leave little room for error and caution investors.
Company outlook
Management provided a medium-term revenue growth estimate of close to 15%. They expect some reduction in interest costs due to rights issue funds and debt repayment. Existing hospitals with expansion plans are expected to deliver at least 75-80% of growth in the next couple of years, with the rest coming from newer centers. The focus remains on margin expansion, cost management, and improving the quality of earnings. Management plans to add 200+ beds across various locations over the next 24 months and aims to add about 1,000 beds by FY30, with 400 through Greenfield and 600 through Brownfield expansion.
Get all details on HCG — P&L, peers, shareholding and more on TradeAlone.
HCG
Healthcare Global Enterprises Limited (NSE: HCG) climbs 5% intraday
Healthcare Global Enterprises Limited (NSE: HCG) stock rises 5% intraday to ₹626.15 despite a 6M trendline breakdown.
Healthcare Global Enterprises Limited (HCG) bounced intraday by +5% despite its 6M trendline status showing a breakdown. The stock has not cleared resistance and remains below both its 6M support and resistance trendlines. HCG operates in the healthcare sector, specifically medical care facilities, and today’s move appears to be a recovery rather than a sector-wide momentum shift.
Technical setup — trendlines & DMA
The current 6M trendline structure for HCG shows a breakdown, with the stock trading below both its support and resistance levels. The 6M support trendline is at ₹646.17, which is 3.20% above the current price, while the resistance trendline is at ₹707.06, 12.92% above. The 50-DMA is below the 200-DMA, indicating a bearish trend, and the stock is currently trading below both moving averages. In terms of its 52W range, HCG is in the middle third, suggesting that a significant portion of its potential move is already priced in.
Snapshot: ₹626.15 on 2026-06-30 (chart frozen at publication)
Fundamentals & business context
With a PE ratio of 619.8 and profit margins at 0.5%, HCG’s valuation appears stretched relative to its current earnings. The revenue CAGR of 14.8% indicates growth, but the declining profit CAGR of -22.3% raises concerns about the sustainability of this growth. Institutional ownership stands at 16.5%, suggesting that while there is some interest from smart money, it is not overwhelmingly positive. There was no specific NSE catalyst today, so the move seems to be more of a technical bounce than a reaction to new fundamental information.
Algorithmic scorecard
The overall algorithmic scorecard for HCG reflects a technically weak but fundamentally stable position. The strongest signals include consistent revenue growth every year, indicating exceptional business stability, and a positive year-over-year gain of 9.0%, showing some resilience. However, the weakest signals are the low profit margin of 0.5%, which leaves little room for error, and the high debt level with a D/E ratio of 1.86, cautioning against further leverage. Additionally, the negligible dividend yield of 0% offers little income for investors, and the bearish trend indicated by the 50-DMA being below the 200-DMA suggests ongoing technical weakness.
Company outlook
Management provided a medium-term revenue growth estimate of close to 15%, with expectations of some reduction in interest costs due to rights issue funds and debt repayment. They anticipate that existing hospitals with expansion plans will contribute 75-80% of growth in the next couple of years, with the remainder coming from newer centers. The focus remains on margin expansion, cost management, and improving the quality of earnings. Management plans to add over 200 beds across various locations within the next 24 months and aims to increase bed capacity by about 1,000 by FY30, with 400 through Greenfield and 600 through Brownfield expansion.
Get all details on HCG — P&L, peers, shareholding and more on TradeAlone.
-
GAIL3 days agoGail (india) Limited Appoints Shri Manoj Kumar Sharma as Director (projects)
-
Basic Materials3 days agoSteel Authority of India Limited (sail) FY’27 Snapshot: Robust Financials and Production Metrics
-
COFORGE2 days agoCoforge Limited (NSE: Coforge) Expands Ai-powered Vehicle Lifecycle Intelligence Capabilities
-
Apparel Manufacturing1 day agoIris Clothings Limited (irisdoreme) Expands Doreme’s Digital Footprint Through Amazon Partnership
-
Information Technology Services1 day agoMagellanic Cloud Limited (NSE: Mcloud) Enters AI Smart Fuel Infrastructure Market with Nayara Energy Contract
-
PREMIERENE1 day agoPremier Energies Limited (premierene) Commissions India’s Largest Solar Cell Facility
-
BIOCON1 day agoBiocon Limited (biocon) Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval
-
DBL1 day agoDilip Buildcon Limited (DBL) Sells Stake in Under-construction Solar Portfolio to Alpha Alternatives